NDAINTRAVENOUSSOLUTION
Approved
Jun 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
ROCURONIUM BROMIDE (rocuronium bromide) by Fresenius Kabi is duration. First approved in 2025.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Rocuronium bromide is a non-depolarizing neuromuscular blocking agent administered intravenously as a solution. It competitively blocks cholinergic receptors at the motor end-plate, with effects antagonizable by acetylcholinesterase inhibitors like neostigmine and edrophonium. This agent is used perioperatively to facilitate intubation and maintain muscle relaxation during anesthesia.
LAUNCH
Early-stage product launch with low immediate visibility; commercial teams will focus on anesthesia market penetration and hospital formulary adoption.
Mechanism of Action
duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797)
Started Oct 2004
149 enrolled
Anesthesia
Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024)
Started Mar 2004
174 enrolled
Anesthesia, General
Career Relevance
Rocuronium bromide is a newly launched product with no established career pipeline yet, representing a ground-floor opportunity for professionals in hospital/perioperative sales and anesthesia market development. Early-stage adoption roles will emphasize formulary strategy, clinician education, and hospital system relationships.
Worked on ROCURONIUM BROMIDE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.